Arsani William - Aug 31, 2021 Form 4 Insider Report for Design Therapeutics, Inc. (DSGN)

Role
Director
Signature
/s/ Mustapha Parekh, Attorney-in-Fact
Stock symbol
DSGN
Transactions as of
Aug 31, 2021
Transactions value $
$618,000
Form type
4
Date filed
9/2/2021, 05:06 PM
Previous filing
Sep 6, 2023
Next filing
Mar 22, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DSGN Common Stock Purchase $618K +40K +1.46% $15.45 2.77M Aug 31, 2021 By Logos Global Master Fund LP F2, F3
holding DSGN Common Stock 1.22M Aug 31, 2021 By Logos Opportunities Fund II, L.P. F1
holding DSGN Common Stock 2.03M Aug 31, 2021 By Logos SPV 1 LP F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person is a managing member of Logos Opportunities Fund II, L.P. and Logos SPV 1 LP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F2 The weighted average purchase price for the transaction was $15.45. The shares were purchased at a range of prices between $15.00 and $15.69, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
F3 Logos Global Management LP ("LGM") is the investment adviser of private funds, including Logos Global Master Fund LP (the "Fund"). Logos GP LLC ("Fund GP") is the general partner of the Fund. The Reporting Person is the Manager of Fund GP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.